اعلان هااااااااااااااام


Translate

Conclusion of Joint Sales Agreement on the overactive bladder therapeutic drug HOB-294 (Asahi Kasei Corporation)

Monday, December 10, 2012

WN.com - Health News
Latest headlines from WN Network
Conclusion of Joint Sales Agreement on the overactive bladder therapeutic drug HOB-294 (Asahi Kasei Corporation)
Dec 10th 2012, 07:40

(Source: Asahi Kasei Corporation) December 10, 2012 Hisamitsu Pharmaceutical Co., Inc. Asahi Kasei Pharma Corp. Hisamitsu Pharmaceutical Co., Inc., (Head Office: Tosu City, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Toshio Asano) hereby announce that as of December 10, 2012, they...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to Conclusion of Joint Sales Agreement on the overactive bladder therapeutic drug HOB-294 (Asahi Kasei Corporation)

Post a Comment